AstraZeneca: Lymphoma trials
The registry lists 22 Lymphoma studies with AstraZeneca as lead sponsor. 3 are open to participants now and 6 have results posted.
Phase 1 14Phase 2 5Phase 3 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell LymphomaNot yet recruitingNCT07882576
- Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)RecruitingNCT07509151Phase 3
- AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.RecruitingNCT06137144Phase 1/2
- Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2Results posted
- Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaCompletedNCT02112526Phase 1Results posted
- Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant LymphomaCompletedNCT01588548Phase 1Results posted
- Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood CancerCompletedNCT01499303Phase 2Results posted
- A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01453205Phase 2Results posted
- A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic LeukemiaTerminatedNCT00587457Phase 1Results posted
- Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLCompletedNCT05958134
- A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
- A Study of AZD0466 in Patients With Advanced Hematologic or Solid TumorsTerminatedNCT04214093Phase 1
- AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedNCT03205176Phase 1
- AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT02780830Phase 1
- Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced TumoursWithdrawnNCT01194193Phase 1
- A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00587015Phase 1
- Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877TerminatedNCT00471367Phase 1
- Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic MalignanciesTerminatedNCT00460460Phase 1
- BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00126646Phase 1
- Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/LeukemiaTerminatedNCT00105313Phase 1
- BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaSuspendedNCT00077493Phase 1